Baumal Caroline

Track

Insider profile

Performance

Overall performance
2.9
Performance over holding periods
2.9
30 days 90 days 120 days
Average return -2% 8.2% 15.1%
Success rate 46% 68% 82%
Transactions
6 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Baumal Caroline's trades of Apellis Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
60.05
Quantity 2,751
Value US$165,207
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-23 2026-01-22
S Sale
78,816 +19.2%
25.87
US$4,667,481 		78,816 +19.2% 25.87 US$4,667,481
2026-01-22 2026-01-22
PrS Proposed sale
90,711
476.44
US$468,602 		90,711 476.44 US$468,602
2026-01-21 2026-01-20
S Sale
38,347 +49.1%
262.72
US$3,895,738 		38,347 +49.1% 262.72 US$3,895,738
2026-01-20 2026-01-20
PrS Proposed sale
1,882
19.79
US$37,250 		1,882 19.79 US$37,250
2026-01-06 2026-01-05
S Sale
3,020 -3.2%
25.53
US$77,097 		3,020 -3.2% 25.53 US$77,097
2026-01-05 2026-01-05
PrS Proposed sale
3,020
25.53
US$77,097 		3,020 25.53 US$77,097
2025-01-21 2025-01-17
S Sale
1,853 -3.3%
29.96
US$55,513 		1,853 -3.3% 29.96 US$55,513
2025-01-17 2025-01-17
PrS Proposed sale
1,853
29.96
US$55,513 		1,853 29.96 US$55,513
2025-01-08 2025-01-06
S Sale
2,816 -4.8%
33.81
US$95,215 		2,816 -4.8% 33.81 US$95,215
2025-01-06 2025-01-06
PrS Proposed sale
2,816
33.81
US$95,213 		2,816 33.81 US$95,213
2024-01-05 2024-01-04
S Sale
2,751 -7.7%
60.05
US$165,207 		2,751 -7.7% 60.05 US$165,207
2024-01-04 2024-01-04
PrS Proposed sale
2,751
60.05
US$165,207 		2,751 60.05 US$165,207